Cargando…
Desymmetrization of pibrentasvir for efficient prodrug synthesis
A novel and practical desymmetrization tactic is described to access a new class of pibrentasvir prodrugs. The homotopic benzimidazoles of pibrentasvir (PIB) are differentiated via a one-pot di-Boc/mono-de-Boc selective N-Boc protection and formaldehyde adduct formation sequence, both enabled by cry...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317637/ https://www.ncbi.nlm.nih.gov/pubmed/34349971 http://dx.doi.org/10.1039/d1sc02396a |
_version_ | 1783730106011746304 |
---|---|
author | Voight, Eric A. Greszler, Stephen N. Hartung, John Ji, Jianguo Klix, Russell C. Randolph, John T. Shelat, Bhadra H. Waters, Jan E. DeGoey, David A. |
author_facet | Voight, Eric A. Greszler, Stephen N. Hartung, John Ji, Jianguo Klix, Russell C. Randolph, John T. Shelat, Bhadra H. Waters, Jan E. DeGoey, David A. |
author_sort | Voight, Eric A. |
collection | PubMed |
description | A novel and practical desymmetrization tactic is described to access a new class of pibrentasvir prodrugs. The homotopic benzimidazoles of pibrentasvir (PIB) are differentiated via a one-pot di-Boc/mono-de-Boc selective N-Boc protection and formaldehyde adduct formation sequence, both enabled by crystallization-induced selectivity. The first step represents the only known application of the Horeau principle of statistical amplification for C(2)-symmetric polyheterocycle regioselective functionalization. The resulting versatile intermediate is employed in the high-yielding preparation of several pibrentasvir prodrug candidates. |
format | Online Article Text |
id | pubmed-8317637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-83176372021-08-03 Desymmetrization of pibrentasvir for efficient prodrug synthesis Voight, Eric A. Greszler, Stephen N. Hartung, John Ji, Jianguo Klix, Russell C. Randolph, John T. Shelat, Bhadra H. Waters, Jan E. DeGoey, David A. Chem Sci Chemistry A novel and practical desymmetrization tactic is described to access a new class of pibrentasvir prodrugs. The homotopic benzimidazoles of pibrentasvir (PIB) are differentiated via a one-pot di-Boc/mono-de-Boc selective N-Boc protection and formaldehyde adduct formation sequence, both enabled by crystallization-induced selectivity. The first step represents the only known application of the Horeau principle of statistical amplification for C(2)-symmetric polyheterocycle regioselective functionalization. The resulting versatile intermediate is employed in the high-yielding preparation of several pibrentasvir prodrug candidates. The Royal Society of Chemistry 2021-06-29 /pmc/articles/PMC8317637/ /pubmed/34349971 http://dx.doi.org/10.1039/d1sc02396a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Chemistry Voight, Eric A. Greszler, Stephen N. Hartung, John Ji, Jianguo Klix, Russell C. Randolph, John T. Shelat, Bhadra H. Waters, Jan E. DeGoey, David A. Desymmetrization of pibrentasvir for efficient prodrug synthesis |
title | Desymmetrization of pibrentasvir for efficient prodrug synthesis |
title_full | Desymmetrization of pibrentasvir for efficient prodrug synthesis |
title_fullStr | Desymmetrization of pibrentasvir for efficient prodrug synthesis |
title_full_unstemmed | Desymmetrization of pibrentasvir for efficient prodrug synthesis |
title_short | Desymmetrization of pibrentasvir for efficient prodrug synthesis |
title_sort | desymmetrization of pibrentasvir for efficient prodrug synthesis |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317637/ https://www.ncbi.nlm.nih.gov/pubmed/34349971 http://dx.doi.org/10.1039/d1sc02396a |
work_keys_str_mv | AT voighterica desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT greszlerstephenn desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT hartungjohn desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT jijianguo desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT klixrussellc desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT randolphjohnt desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT shelatbhadrah desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT watersjane desymmetrizationofpibrentasvirforefficientprodrugsynthesis AT degoeydavida desymmetrizationofpibrentasvirforefficientprodrugsynthesis |